| 宋政炜,陈 飞,王晓光.SLC29A1基因C177G单核苷酸多态性与晚期胰腺癌吉西他滨化疗耐药及预后相关性的研究[J].肿瘤学杂志,2016,22(3):209-213. |
| SLC29A1基因C177G单核苷酸多态性与晚期胰腺癌吉西他滨化疗耐药及预后相关性的研究 |
| The Relevance of SLC29A1 Gene Single Nucleotide Polymorphism with Resistance of Gemcitabine Chemotherapy and Prognosis in Advanced Pancreatic Cancer |
| 投稿时间：2015-12-05 |
| DOI：10.11735/j.issn.1671-170X.2016.03.B011 |
|
 |
| 中文关键词: 胰腺肿瘤 基因，SLC29A1 突变 吉西他滨 耐药 预后 单核苷酸多态性 |
| 英文关键词:pancreatic neoplasms gene,SLC29A1 mutation gemcitabine resistance prognosis single nucleotide polymorphism |
| 基金项目:嘉兴市科技局社会发展项目（2014AY210） |
|
| 摘要点击次数: 2519 |
| 全文下载次数: 685 |
| 中文摘要: |
| 摘 要：［目的］ 研究晚期胰腺癌患者SLC29A1基因177位点单核苷酸多态性(single nucleotide polymorphism，SNP)分布情况，并探索其与吉西他滨化疗耐药及与预后的关系。［方法］ 对晚期胰腺癌患者66例，抽提外周血标本DNA，应用DNA直接测序法明确SLC29A1基因177位点SNP序列，结合临床资料，分析SLC29A1基因SNP对晚期胰腺癌吉西他滨化疗耐药性及生存期的影响。［结果］ 66例患者SLC29A1基因C177G突变型为32例，其中吉西他滨化疗耐药者为25例，耐药率达78.1%；野生型34例，其中吉西他滨化疗耐药者17例，耐药率为50.0%。SLC29A1基因C177G突变型组胰腺癌患者吉西他滨化疗有效率明显较野生型组低，而耐药率明显较野生型组高，两者差异有统计学意义（P<0.05）。SLC29A1基因C177G突变型组胰腺癌患者的6个月生存率为72.3%，野生型组为83.7%，两者差异无统计学意义（P>0.05）；而前者的1年生存率为29．8%，后者为64.3%，差异有统计学意义（P<0.05）。［结论］ 晚期胰腺癌患者SLC29A1基因C177G SNP与胰腺癌患者吉西他滨化疗耐药及预后有相关性，可能成为有效预判胰腺癌患者吉西他滨化疗耐药及预后的敏感指标。 |
| 英文摘要: |
| Abstract：［Purpose］ To identify the distribution of single nucleotide polymorphism(SNP) of SLC29A1 gene rs177 in advanced pancreatic cancer patients，and to investigate its relationship with resistance of gemcitabine chemotherapy and prognosis.［Methods］ The total DNA from peripheral blood samples of 66 cases with advanced pancreatic cancer were extracted，and SNP sequences of SLC29A1 gene(rs177) were detected by directed DNA sequencing.The impact of SLC29A1 gene SNP on resistance of gemcitabine chemotherapy and survival were analyzed. ［Results］ Among 66 enrolled patients，SLC29A1 gene C177G mutation type was presented in 32 cases，including 25 cases with gemcitabine chemotherapy resistance；wild type was detected in 34 cases，including 17 cases with gemcitabine chemotherapy resistance. The resistance rate of SLC29A1 gene C177G mutation type group was 78.1%，which was significantly higher than that of wild type group(50.0%)（P<0.05）. The difference of the 6 months survival rate was not significantly different between C177G mutation type group and wild type group(72.3% vs 83.7%，P>0.05)；while the 1-year survival rate was significantly different between the two groups (29．8% vs 64.3%，P<0.05).［Conclusion］ SLC29A1 gene C177G SNP has correlation with resistance of gemcitabine chemotherapy and prognosis in advanced pancreatic cancer patients，and it might serve as a useful marker for the prediction of resistance of gemcitabine chemotherapy and prognosis in patients with advanced pancreatic cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |